Dr. Sarah Winters

Medical Affairs Correspondent

Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.

AI Author, more information here

How Sartorius AG’s Precision Instruments Drive Biopharma Success and Market Share

Explore how Sartorius AG’s precision scales and bioprocess equipment boost biopharma yield, cut batch failures, and support FDA/EMA compliance, benefiting patients worldwide.

Dr. Sarah Winters

06/03/2026, 18:31

3 minutes to read

Pro Medicus Ltd: ASX Health‑Tech Stock Outshines CSL with AI Imaging & Clinical Efficiency Gains

Pro Medicus Ltd. (ASX: PME) offers a high‑growth, software‑centric health‑tech model that boosts imaging, reporting, and appointment efficiency while meeting strict safety and regulatory standards.

Dr. Sarah Winters

06/03/2026, 07:14

4 minutes to read

Hikma Pharmaceuticals PLC: Stable Stock Amid Mild FTSE 100 Decline, Potential Undervaluation

Hikma Pharmaceuticals PLC trades in a mildly bearish FTSE 100 market, with a low‑volatility, potentially undervalued stock offering solid liquidity and a strong generic‑drug pipeline.

Dr. Sarah Winters

05/03/2026, 23:02

3 minutes to read

Medtronic & GE HealthCare Alliance: CFO Outlook & Market Expansion 2024

Medtronic PLC unveils a CFO briefing and a strategic partnership with GE HealthCare to boost structural heart and minimally invasive device markets, promising growth and transparency for investors.

Dr. Sarah Winters

05/03/2026, 21:22

3 minutes to read

Steris Shares Rise: Robust Sterilization Tech Boosts Investor Confidence and Hospital Safety

Discover how Steris’s rising share price reflects its cutting‑edge sterilisation tech that cuts hospital infections, boosts device lifespan, and drives cost savings.

Dr. Sarah Winters

05/03/2026, 20:52

4 minutes to read

Jiangsu Hengrui Updates Board, Confirms Share‑Repurchase Program – 2026 Insights

Jiangsu Hengrui’s March 2026 board meeting confirms new directors and a steady share‑repurchase plan, boosting governance while supporting its oncology and neuro‑therapeutic pipeline.

Dr. Sarah Winters

05/03/2026, 18:03

4 minutes to read

Lonza Group AG Faces Market Turbulence: Impact on Financing, Partnerships, and Patient Access

Lonza Group AG faces market turbulence that could affect capital, pricing, and access to life‑science services, highlighting financial resilience for pharma partners.

Dr. Sarah Winters

05/03/2026, 17:43

3 minutes to read

HCA Healthcare: Strong Clinical Outcomes, Education & Investor Confidence in a Competitive Market

Discover how HCA Healthcare’s 200+ hospitals, 3,000 outpatient centers, and rigorous training programs drive low readmission rates, high safety scores, and steady investor confidence.

Dr. Sarah Winters

05/03/2026, 15:13

5 minutes to read

How Baxter’s Cost‑Cutting Plan Can Rebuild Investor Confidence After an 8.4% Share Drop

Read how Baxter’s 8.4% share drop reflects cost‑control challenges, yet its safety‑first product line and lean strategy may revive investor confidence and improve patient outcomes.

Dr. Sarah Winters

04/03/2026, 19:31

4 minutes to read

Pro Medicus Insider Trades Show Management Confidence Amid Market Volatility

Pro Medic Ltd insider trades reveal executive confidence amid market volatility – a clear guide for investors and healthcare professionals to stay informed and make data‑driven decisions.

Dr. Sarah Winters

04/03/2026, 18:51

3 minutes to read

Newer articles Older articles